| Item Type | Name |
|
Concept
|
Interleukin-2
|
|
Concept
|
Interleukin-1
|
|
Concept
|
Interleukin-3
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Receptors, Interleukin-6
|
|
Concept
|
Receptors, Interleukin-2
|
|
Concept
|
Interleukin-4
|
|
Concept
|
Interleukin-12
|
|
Concept
|
Interleukin-23
|
|
Concept
|
Interleukin-23 Subunit p19
|
|
Academic Article
|
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
|
|
Academic Article
|
Liver of MRL/lpr mice contain interleukin-4-producing lymphocytes and accessory cells that support the proliferation of Th2 helper T lymphocyte clones.
|
|
Academic Article
|
Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
|
|
Academic Article
|
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
|
|
Academic Article
|
Blocked Ras activation in anergic CD4+ T cells.
|
|
Academic Article
|
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity.
|
|
Academic Article
|
Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.
|
|
Academic Article
|
CD28 is not required for c-Jun N-terminal kinase activation in T cells.
|
|
Academic Article
|
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12.
|
|
Academic Article
|
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity.
|
|
Academic Article
|
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
|
|
Academic Article
|
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
|
|
Academic Article
|
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
|
|
Academic Article
|
Integrating IL-12 into therapeutic cancer vaccines.
|
|
Academic Article
|
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
|
|
Academic Article
|
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes.
|
|
Academic Article
|
Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration.
|
|
Academic Article
|
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
|
|
Academic Article
|
CD4+ murine T cell clones that express high levels of immunoglobulin binding belong to the interleukin 4-producing T helper cell type 2 subset.
|
|
Academic Article
|
Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.
|
|
Academic Article
|
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
|
|
Academic Article
|
Evidence implicating utilization of different T cell receptor-associated signaling pathways by TH1 and TH2 clones.
|
|
Academic Article
|
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
|
|
Academic Article
|
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma.
|
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
|
Academic Article
|
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
|
|
Academic Article
|
Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells.
|
|
Academic Article
|
Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors.
|
|
Academic Article
|
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells.
|
|
Academic Article
|
Regulation of T-cell activation: differences among T-cell subsets.
|
|
Academic Article
|
An adenoviral vector for probing promoter activity in primary immune cells.
|
|
Academic Article
|
Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.
|
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.
|
|
Academic Article
|
Differential activation of Th1 and Th2 CD4+ cells by murine brain microvessel endothelial cells and smooth muscle/pericytes.
|
|
Academic Article
|
Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways.
|
|
Academic Article
|
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells.
|
|
Academic Article
|
"Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.
|
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor.
|
|
Academic Article
|
Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways.
|
|
Academic Article
|
Control of T lymphocyte signal transduction through clonal anergy.
|
|
Academic Article
|
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cells.
|
|
Academic Article
|
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
|
|
Academic Article
|
Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma.
|
|
Academic Article
|
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
|
|
Academic Article
|
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
|
|
Academic Article
|
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
|
|
Academic Article
|
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
|
|
Academic Article
|
Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma.
|
|
Academic Article
|
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
|
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|